Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

an FAK inhibitor addition to avutometinib augmented tumor regression with stronger inhibition of MAPK, PI3K and YAP/TEAD signaling than either agent alone The combination of avutometinib ...

VT3989 is a transcriptional enhanced associate domain (TEAD) autopalmitoylation inhibitor that blocks the palmitoylation of TEAD protein family members to target the Hippo pathway. RA Capital ...

Proceeds will support the continued development of what the company describes as its first-in-class and best-in-class transcriptional enhanced associate domain autopalmitoylation (TEAD) inhibitor, ...